We read the article ''Admission Endocan Level may be a Useful Predictor for In-Hospital Mortality and Coronary Severity Index in Patients With ST-Segment Elevation Myocardial Infarction'' by Kundi et al 1 with interest. Kundi et al 1 assessed the potential association of serum endocan level with the severity of coronary artery disease (CAD) and in-hospital mortality in patients with ST-segment elevation myocardial infarction (STEMI). They demonstrated that a high endocan level on hospital admission was an independent predictor of worse cardiovascular (CV) outcomes and high SYNTAX scores in these patients.
The SYNTAX score is an angiographic tool used to grade the severity and complexity of CAD. Also, the SYNTAX score predicts long-term mortality and morbidity in several patient populations. 2 Endocan (endothelial cell-specific molecule 1) is a marker for vascular pathology and a mediator of inflammation, strongly associated with CV disease. 3 Furthermore, Yilmaz et al reported that plasma endocan levels can predict overall and CV mortality as well as CV events in patients with chronic kidney disease. 4 Recently, the neutrophil to lymphocyte ratio (NLR), platelet to lymphocyte ratio (PLR), and monocyte to high-density lipoprotein cholesterol (MHR) have been used as inflammatory biomarkers and independent predictors of atherosclerosis and CV events. [5] [6] [7] In the study by Kundi et al, 1 it was clear that the patients in the STEMI group had higher NLR, PLR, and MHR as well as endocan and highsensitivity C-reactive protein levels compared with the control group. However, this study did not mention the combinations of these inflammatory biomarkers including NLR, PLR, and MHR. Besides, they did not indicate which possible confounding factors were tested in the univariate regression model. In addition to this, these parameters were not included in the multivariate logistic regression analysis. Therefore, the study findings as regards independent predictors of in-hospital mortality and high SYNTAX score may be misleading. Furthermore, their study lacks any angiographic data that the angiographic characteristics of study population such as single versus triple vessel disease, mean or median stenosis, number and length of lesions, and the number of total occlusions should be stated in the text. In conclusion, endocan may be a diagnostic and prognostic biomarker for CV disease. 8 However, its role in coronary severity index, CV events, and in-hospital mortality among patients with STEMI undergoing primary percutaneous coronary intervention should be interpreted after considering several confounding factors.
